Core Viewpoint - The company has successfully developed and marketed a freeze-dried human rabies vaccine using human diploid cells, which is recognized as a gold standard for rabies prevention and has received various national honors [3][4]. Company Overview - The company specializes in the development and sale of vaccines, with its core product being the freeze-dried human rabies vaccine, the first of its kind in China [3]. - The rabies vaccine is produced using advanced technology that eliminates animal cell residues, ensuring high safety and immunogenicity [3][4]. Industry Development - The global vaccine market is projected to reach approximately $83.1 billion by 2025 and $131 billion by 2030, driven by increasing health awareness and demand for infectious disease prevention [4]. - The Chinese vaccine industry is transitioning from scale expansion to innovation-driven growth, with a focus on advanced technologies such as mRNA and recombinant protein vaccines [5]. - There is a significant global demand for vaccines, with 68 countries reporting vaccine shortages in 2023, creating opportunities for Chinese vaccine companies to expand internationally [5]. Competitive Landscape - The vaccine industry is characterized by high capital investment, high research and development risks, and long product development cycles, which create substantial barriers to entry [6][7]. - The Chinese vaccine market is currently fragmented, with a mix of state-owned, multinational, and private enterprises competing for market share [8]. - Regulatory changes and the implementation of new laws are expected to increase industry consolidation, leading to a higher concentration of vaccine producers in the market [8].